Global Lymphedema Treatment Market Overview
The Lymphedema Treatment Market Size was valued at USD 0.5 billion in 2022 and is projected to grow from USD 0.54 Billion in 2023 to USD 1.06 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.80% during the forecast period (2023 - 2032).Lymphedema's rising frequency as well as other chronic illnesses like cancer that it is caused by are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Lymphedema Treatment Market Trends
- Growing lymphedema population is driving the market growth
Market CAGR for lymphedema treatment is being driven by the rising number of lymphedema people. The market is expected to develop worldwide due to the growing frequency of lymphedema patients. The rise in cancer incidence will probably present a tonne of market expansion potential. The development of a disease or the use of medications that impair lymph node draining can cause lymphedema in cancer patients, according to the U.S. Department of Health & Human Services. For instance, this condition may manifest days after breast cancer therapy or up to 30 years afterward. In addition, 80% of patients experience the beginning 3 years after the procedure. In addition, a significant proportion of patients, mostly women, experience lower limb lymphedema following gynecologic cancer therapy, with ovarian cancer survivors having a lower prevalence (7%) and vulvar cancer survivors having a higher majority (37%) of cases. Additionally, two years after surgery, the frequency of arm lymphedema ranged from 7 to 56%.
The need for healthcare facilities has been exacerbated by rising health spending and increased investment in research and development for medication discoveries. The market is expanding due to the increased incidence of lymphedema therapy and the increasing number of individuals seeking treatment.
It is projected that increasing spending on patient care and investments in COVID-19 vaccine development would limit funding for research efforts in the market for treating lymphedema. Academic and scientific organizations have postponed their study in this area due to the epidemic. The expansion of the lymphedema treatment market is also projected to be hampered in the next years by the fall in corporate investment and government assistance. Thus, driving the Lymphedema Treatment market revenue.
Lymphedema Treatment Market Segment Insights
Lymphedema Treatment Type Insights
The Lymphedema Treatment market segmentation, based on type, includes primary lymphedema and secondary lymphedema. The secondary lymphedema segment dominated the market, accounting for 65% of market revenue. Certain malignant disorders, such as Hodgkin's disease and Kaposi sarcoma, can lead to secondary lymphedema, a condition characterized by swelling of the soft tissues where an excessive quantity of lymph has collected. Secondary lymphedema can also arise following the excision of lymph nodes during various cancer operations, particularly for breast and prostate cancers, as well as from several non-malignant conditions, such as lipedema.
Lymphedema Treatment Affected Area Insights
The Lymphedema Treatment market segmentation, based on the affected areas, includes the lower extremity, upper extremity, and genitalia. The Lower extremity category generated the most income, as lymphedema mainly affected the lower portion.
Figure 1: Lymphedema Treatment Market, by Affected Area, 2022 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Lymphedema Treatment Insights
The Lymphedema Treatment market segmentation is based on treatment compression devices & bandaging, laser therapy, drug therapy and surgery. The compression devices & bandaging segment dominated the market. Compression becomes crucial for treating the illness. Although clothes are frequently designed to be worn all day unless otherwise specified, they can be removed for sleeping. Following completion of decongestive treatment, elastic compression garments are put on the afflicted limb to preserve edema reduction. Clothing that is non-elastic offers confinement and reduction. Prices, possibilities, and stylistic options are all very different. The patient's best course of action can be determined with the assistance of a qualified lymphedema therapist or professional garment fitter.
Lymphedema Treatment End User Insights
The Lymphedema Treatment market segmentation is based on end-user includes hospitals and clinics, clinical research organizations, and research & academic institutes. The hospitals and clinics segment dominated the market. The significant number of patients who come directly to the hospital for Lymphedema diagnosis and treatment can be blamed for the segment's considerable proportion. In addition, the segment's expansion is projected to be fueled by the increased acceptance of less invasive procedures combined with novel and sophisticated therapies. Additionally, the segment is anticipated to see significant growth potential due to the rising number of hospitals providing Lymphedema treatments in emerging nations.
Lymphedema Treatment Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Lymphedema Treatment market will dominate this market; It is projected that the healthcare industry's increasing use of technology will fuel market expansion in North America. The growing awareness of IgG4-related disorders is anticipated to present enormous market expansion prospects. Lymphedema's high incidence in the US is expected to fuel market expansion. Additionally, the increasing frequency of chronic conditions like cancer that cause secondary lymphedema is anticipated to fuel market expansion in North America.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: LYMPHEDEMA TREATMENT MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Lymphedema Treatment market accounts for the second-largest market share. The market for lymphedema treatments in this area is projected to rise due to leading industry participants' cooperation initiatives and the development of new products. The increased incidence of lymphedema also contributes to expanding the market in this area. Further, the German Lymphedema Treatment market held the largest market share, and the UK Lymphedema Treatment market was the fastest-growing market in the European Region.
The Asia-Pacific Lymphedema Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. The rapid expansion of the market can be linked to the rise in chronic illness prevalence, the expansion of the healthcare system, and the expansion of government and pharmaceutical company research programs to create novel lymphedema treatment approaches. Moreover, China's Lymphedema Treatment market held the largest market share, and the Indian Lymphedema Treatment market was the fastest-growing market in the Asia-Pacific region.
Lymphedema Treatment Key Market Players & Competitive Insights
The market for lymphedema treatments will expand due to major industry participants spending a lot of money on research & development to diversify their product offerings. Market participants also engage in various strategic initiatives to broaden their worldwide reach. Significant market developments include new product launches, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Lymphedema Treatment industry must provide affordable products to grow and thrive in a more competitive market.
Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers utilize in the Lymphedema Treatment industry to benefit customers and expand the market sector. In recent years, the Lymphedema Treatment industry has offered some of the most significant advantages. Major players in the Lymphedema Treatment market, including Sakra World Hospital, and others, are attempting to increase market demand by investing in research and development operations.
The first multinational corporation (MNC) hospital in India, Sakra World Hospital (A unit of Takshasila Hospitals Operating Private Limited), is dedicated to providing cutting-edge healthcare that raises the worth of human life. To offer the most advanced medical technology and signal a shift in the existing healthcare systems and procedures, Sakra integrates the synergies of these substantial businesses. Sakra is committed to promoting the community's health. In July 2021, On World Plastic Surgery Day, Sakra World Hospital opened a "Comprehensive Lymphedema Care Centre to provide patients with lymphedema (body swelling brought on by a buildup of lymph fluid) with comprehensive medical care and aid them in improving their quality of life.
Their distinctive offering consists of cutting-edge, scientifically tested pneumatic compression devices and continuity of care services offered by a national network of product specialists and trainers, reimbursement experts, patient advocates, and clinical professionals. Tens of thousands of patients receive the at-home care required to effectively manage their chronic diseases each year thanks to this mix of goods and services. In September 2021, The assets of International Biophysics Corporation, which created and produced the AffloVest respiratory therapy device, have been bought by Tactile Systems Technology, Inc.
Key Companies in the Lymphedema Treatment market include
-
Mego Afek Ltd. (US)
-
Bio Compression Systems Inc. (US)
-
SIGVARIS (Switzerland)
-
Herantis Pharma PLC (Finland)
-
3A Health Care (Italy)
-
Wright Therapy Products (Germany)
-
Tactile Systems Technology Inc. (US)
-
Lohmann & Rausher (Germany)
-
Juzo (Germany)
-
3M (US)
-
Cardinal Health (US)
-
Huntleigh Healthcare Limited (UK)
-
Koya Medical (US)A
-
vet Pharmaceuticals (US)
-
AIROS Medical Inc. (US)
-
Convatec (UK)
Lymphedema Treatment Industry Developments
January 2021:According to Koya Medical, a Series B of USD 11 million, a healthcare company specializing in treating lymphedema and venous disease, an investment round has been closed. Aphelion Capital has joined previous investors Zühlke Ventures, Scientific Health Development Partners, Bolt, and Inner Products Partners in this round.
January 2020:The new AIROS 8 Sequential Compression Therapy device and garment system received FDA 510(k) certification, according to AIROS Medical, Inc. This medical technology firm specializes in compression therapy devices to treat lymphedema and cancer-associated venous issues.
Lymphedema Treatment Market Segmentation
Lymphedema Treatment Type Outlook
-
Primary Lymphedema
-
Secondary Lymphedema
Lymphedema Treatment Affected Area Outlook
-
Lower Extremity
-
Upper Extremity
-
Genitalia
Lymphedema Treatment Outlook
Lymphedema Treatment End-User Outlook
Lymphedema Treatment Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 0.5 billion |
| Market Size 2023 |
USD 0.54 billion |
| Market Size 2032 |
USD 1.06 billion |
| Compound Annual Growth Rate (CAGR) |
8.80% (2023-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2032 |
| Historical Data |
2018- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Type, Affected Area, treatment, End User, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
3A Health Care (Italy), Bio Compression Systems, Inc. (US), Devon Medical Products (US), HERANTIS PHARMA PLC (Finland), Lohmann & Rauscher (Germany), Mego Afek Ltd (US), SIGVARIS (Switzerland), Tactile Systems Technology Inc. (US), Wright Therapy Products (BSN Medical) (Germany) |
| Key Market Opportunities |
Increased research & development in the market |
| Key Market Dynamics |
Increasing cancer cases Favorable reimbursement policies |
Frequently Asked Questions (FAQ) :
The Lymphedema Treatment market size was valued at USD 0.5 Billion in 2022.
The market is projected to grow at a CAGR of 8.80% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are 3A Health Care (Italy), Bio Compression Systems, Inc. (US), Devon Medical Products (US), HERANTIS PHARMA PLC (Finland), Lohmann & Rauscher (Germany).
The secondary Lymphedema Treatment category dominated the market in 2022.
The hospital and clinics had the largest share in the market.
